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ABSTRACT 
SULFORAPHANE PREVENTS ACETAMINOPHEN-INDUCED HEPATIC INJURY IN MICE 
Robin H. Schmidt 
11/29/2011 
Sulforaphane (SFN), an isothiocyanate found in cruciferous vegetables, is known to 
confer antioxidant protection in vivo. Rather than directly reacting with free radicals, however, 
SFN works by inducing Nrf2, a transcription factor that binds to the promoter regions of several 
known antioxidant genes and enhances detoxification. Because oxidative stress is a major 
contributor to acetaminophen (APAP)-induced hepatotoxicity, SFN may defend the liver against 
APAP overdose by activating the Nrf2 pathway and increasing endogenous antioxidant response. 
To test this hypothesis, mice were pre-treated with SFN for four days, injected with APAP on the 
fifth day, and sacrificed shortly thereafter. APAP overdose caused massive hepatic injury, as 
shown by increases in serum liver enzyme activity and lipid peroxidation. APAP overdose also 
manifested as decreases in total glutathione and glutathione reductase activity. SFN 
administration clearly prevented these manifestations of liver injury, however: increases in serum 
liver enzyme activity and lipid peroxidation were blunted, while total glutathione and glutathione 
reductase activity remained similar to those of control animals. SFN treatment did not affect the 
catalytic activity of acetaminophen-metabolizing enzyme CYP2E1, but did increase nuclear 
accumulation of Nrf2, suggesting that SFN acts primarily through the Nrf2 pathway. In summary, 
these data support the hypothesis that sulforaphane attenuates acute acetaminophen-induced 
liver injury. This decrease in injury results from the increased availability of glutathione to react 
with toxic metabolites of acetaminophen. 
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INTRODUCTION 
The byproducts of hepatic drug metabolism are often oxidants or electrophiles which 
readily react with important biological moleculesY-3) Under ideal conditions, reactive metabolites 
are removed from the liver by a multitude of enzymes that have evolved for this purpose. Yet in 
certain situations these metabolites may accumulate. The resulting condition is broadly termed 
"oxidative stress" and leads to potentially dangerous alterations in hepatic structure and 
function.(4) 
Oxidative stress is demonstrably reduced in vitro with direct-acting antioxidants such as 
tocopherols and melatonin. In animal and human studies, however, the benefits of antioxidant 
use are far less apparent. The reason for this experimental incongruity is still unclear. One 
suggestion is that, in whole animal models, it is difficult to achieve adequate antioxidant 
concentrations anhe desired site of action. (5; 6) Alpha-tocopherol, for example-;1ends to 
accumulate in cellular membranes, and therefore has limited ability to quench reactive molecules 
within the cytoplasm. Many free radical-scavenging agents are also hypothesized to act as pro-
oxidants, which may explain the observation that high doses of antioxidant vitamins actually 
increase morbidity and mortality. (7-10) 
Many researchers are now looking toward the use of indirect antioxidants as a treatment for 
oxidative stress. In contrast to direct agents, such as the previously-mentioned antioxidant 
vitamins, indirect antioxidants do not interact with reactive metabolites or free radicals. (11) 
Sulforaphane (SFN), an isothiocyanate derived from Brassica vegetables, is a prototypical 
indirect antioxidant. Rather than reducing reactive metabolites, SFN induces Nrf2, a transcription 
factor that regulates cellular defense against toxicity.(12; 13) The proposed mechanism of defense 
is an interaction between SFN and Keap1, a substrate adaptor for the E3 ubiquitin ligase CuI3.(14; 
15) During homeostasis Nrf2 is 'found in the cytoplasm, where it binds Keap1. In the absence 
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of stressors, Nrf2 and Keap1 remain bound, and Keap1 will eventually facilitate proteasomal 
degradation of Nrf2. Conversely, if electrophiles or oxidants are present, they will disrupt the 
bond between Nrf2 and Keap1, allowing Nrf2 to translocate to the nucleus and bind antioxidant 
response elements (AREs) in DNA.(16; 17) In particular, it is the electrophilic central carbon atom 
of SFN's -N=C=S side chain which theoretically disrupts the Nrf2-Keap1 bond, as this carbon can 
readily form thionoacyl adducts.(lS; 19) Following alkylation, Nrf2 would then be free to bind AREs 
which regulate the transcription of genes encoding cytoprotective enzymes, e.g., heme 
oxygenase 1 (Fig. 1). 
The purpose of the present study was to determine the ability of SFN to prevent toxicity in an 
established model of oxidative stress. Acetaminophen (APAP) was chosen because, though it is 
safe within its intended dose range, it causes a concentration-dependent and easily reproducible 
injury to hepatocytes at larger doses.(20) APAP's toxicity is mediated in part by its oxidative 
byproduct NAPQI, which can drastically deplete glutathione reserves.(21; 22) Despite substantial 
evidence of SFN's protective properties, there are no FDA-approved therapies for oxidative injury 
that incorporate indirect antioxidants. The results presented here further support the need for 
indirect antioxidants in clinical practice. 
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MATERIALS AND METHODS 
Animals and treatments 
Male C57BLl6J mice (6-8 weeks old) were purchased from Jackson Laboratory (Bar 
Harbor, ME). Mice were housed in a pathogen-free barrier facility accredited by the Association 
for Assessment and Accreditation of Laboratory Animal Care, and procedures were approved by 
the local Institutional Animal Care and Use Committee. All diets were switched from standard 
laboratory chow to AIN-76A purified diet one week prior to the study, since impurities found in 
standard laboratory chow may create experimental variability. Food and tap water were allowed 
ad libitum. 
In experiments designed to test the effects of SFN alone, mice were administered SFN 
(10 mg/kg i.g. diluted in water; LKT Laboratories, St. Paul, MN) or water for 4 days q.a.m. Groups 
-of mice were selected to be euthanized at six or 24 hours after the last i.g. dOSing. In experiments 
designed to test the protective effects of SFN on APAP overdose, mice were administered SFN 
(10 mg/kg i.g.) or water for 4 days q.a.m. On the following day, mice were injected with APAP 
(300 mg/kg i.p.; Sigma-Aldrich, St. Louis, MO). Six hours after APAP injection (24 h after last i.g. 
SFN or water), the mice were euthanized. 
Regardless of experimental treatment, procedures used in harvesting tissue were the 
same. Mice were euthanized with ketamine/xylazine (100/15 mg/kg i.m.), and their blood and 
livers were collected for later analysis. Blood was collected from the vena cava just prior to 
sacrifice by exsanguination and citrated plasma was stored at -80°C for later analysis. Portions 
of liver tissue were snap-frozen in liquid nitrogen, frozen-fixed in OCT-Compound (Tissue-Tek 
OCT compound, Sakura Finetek, Torrance, CA), or fixed in 10% neutral buffered formalin for 
subsequent sectioning and mounting on microscope slides. Some snap-frozen liver was 
homogenized in 4.4% metaphosphoric acid for detection of glutathione. 
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Biochemical analyses and histology 
Plasma levels of aminotransferases (AL T) and hepatic levels of triglycerides were 
determined using standard kits (Thermotrace, Melbourne, Australia). Paraffin-embedded 
sections of liver were stained with hematoxylin & eosin (H&E). Red blood cell extravasation in 
the livers was assessed by staining tissue sections for chloroacetate esterase, a marker for 
RBCs, using the naphthol AS-D chloroacetate esterase (CAE) kit (Sigma, St. Louis MO). 
Adducts of 4-hydroxynonenal (lipid peroxidation) were detected by immunohistochemistry as 
described previously.(23) 
Quantitation of glutathione content and glutathione reductase activity 
Total cellular glutathione content was quantitated colorimetrically from liver samples using a 
modified version of the method described by Rahman. (24) A 10% solution of tissue homogenate 
(w/v) was prepared in 4.4% meta phosphoric acid using an all-glass Tenbroeck homogenizer, and 
kept on ice. After standing for 20-40 min, the homogenate was centrifuged for 1 min (10,000 x 
g), and the supernatant collected. Twenty tJl of the supernatant were added to each well of a 
microtiter plate and incubated with 120 tJl of a solution containing potassium phosphate buffer 
(pH 7.S), 10 mM EDTA, 2 mM S,S'-dithiobis(2-nitrobenzoic acid) (DTNB) and 230 U/mL 
glutathione reductase (GR, EC 1.6.4.2, Sigma-Aldrich, St. Louis, MO). After allowing 60 seconds 
for conversion of GSSG to GSH, 60 tJl of buffered NADPH solution was added, and the 
absorbance was read for S minutes at 412 nm during the linear portion of the reaction. Total 
glutathione was calculated from a standard curve prepared with purified GSH. Results were 
reported as nmol GSH per g tissue wet weight. 
To determine GR activity, liver tissue was homogenized in a phosphate buffer 
(pH 7.S) containing 1 mM DTT and centrifuged for 10 min (10,000 x g) to clear the homogenate. 
Twenty tJl of each sample were then added to each well of a microtiter plate and incubated for 60 
sec with a solution containing phosphate buffer, 2 mM GSSG, and 1 mM NADPH. The 
absorbance was read for S min at 412 nm, and enzyme activity was calculated from a standard 
curve of purified GR. The protein concentration of the homogenate was subsequently measured 
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according to the method of Bradford. (25) After adjusting for protein concentration, glutathione 
reductase activity was reported as units of activity/mg protein. 
Microsomal isolation and cytochrome P450 activity determination 
Expression and activity data were obtained for cytochrome P450 2E1 (CYP2E1), the 
microsomal enzyme that generates NAPQI. Microsomes were isolated according to a protocol 
adapted from those of COX(26) and Falkner.(27) Briefly, liver tissue was kept on ice and 
homogenized with a Teflon pestle in a buffer containing 50 mM Tris-HCI (pH 7.4), 225 mM 
mannitol and 75 mM sucrose. The homogenate was spun at 15,000 x 9 for 20 minutes, after 
which the supernatant was collected and spun at 436,000 x 9 for an additional 20 min. The pellet 
remaining was next resuspended in a buffer of 250 mM mannitol, 0.5 mM EGTA, and 5mM 
HEPES (pH 7.4) and centrifuged again at 9,000 x 9 for 30 min. The supernatant resulting from 
this centrifugation was collected, assessed for protein concentration, and stored at -SO° until 
kinetic analysis. 
CYP2E1-mediated conversion of p-nitrophenol to 4-nitrocatechol was measured by 
spectrophotometer as described previously. (28; 29) Isolated microsomes were added to each well 
of a microtiter plate along with an assay buffer containing 100 mM sodium phosphate (pH 6.S), 
0.1 mM p-nitrophenol, and 1mM NADPH. After incubating for 10 min at 37°, the absorbance was 
read at 4S0 nm for 12 min and concentration values were interpolated from a standard curve of 4-
nitrocatechol dissolved in sodium phosphate buffer. Activity was determined from the change in 
4-nitrocatechol concentration per unit time. 
Immunoblots 
All buffers used for protein extraction contained protease, tyrosine phosphatase, and 
serine/threonine phosphatase inhibitor cocktails (Sigma, St. Louis, MO). Nuclear proteins were 
isolated according to the method of Dignam et al.(30) A sample of liver tissue (50-100 mg) from 
each animal was homogenized in a pre-chilled Dounce glass tissue grinder containing 500 IJL 
hypotonic buffer (1.5 mM MgCI2, 1 mM KCI, .5 mM DTT,10 mM HEPES, pH 7.6). The 
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homogenate was placed on ice for 15 minutes, then vigorously mixed with 30 IJl of a 10% NP-40 
solution and centrifuged for 30 sec at 16,000 x g. The supernatant (cytosolic fraction) was 
transferred to a separate tube and the pellet was mixed with 70 IJl of resuspension buffer (50% 
v/v glycerol, 420 mM NaCI, .25 mM EDTA, .5 mM DTT, 10 mM HEPES, pH 7.6). After the 
resuspended samples were agitated on ice for 15 min, they were then spun for 5 min at 16,000 x 
g, and the supernatant (nuclear fraction) was collected and stored at -80°C. 
Nuclear and cytosolic proteins were loaded onto SDS-polyacrylamide gels of 10% (w/v) 
acrylamide followed by electrophoresis and Western blotting onto PVDF membranes (Hybond P, 
GE Healthcare, Piscataway, NJ). Primary antibodies against Nrf2 and GAPDH (Santa Cruz 
Biotechnology, Inc., Santa Cruz, CA) were used. Bands were visualized using an ECl kit 
(Pierce, Rockford, Il) and Hyperfilm (GE Healthcare, Piscataway, NJ). 
RNA isolation and real-time RT -peR 
Message levels of select genes were detected by real-time reverse-transcriptase PCR. 
Total RNA was extracted from liver tissue samples by a guanidium thiocyanate-based method 
(Tel-Test, Austin, TX). RNA concentrations were determined spectrophotometrically, and cDNA 
was synthesized from 1 IJg total RNA using an MMlV reverse transcriptase kit (Quanta 
Biosciences, Gaithersburg, MD). The cDNA was added to a mixture containing pre-made primers 
and probes (Applied Biosystems, Foster City, CA) and a ready-to-use reaction buffer (Quanta). 
Amplification reactions were carried out in the StepOne™ sequence detection system (Applied 
Biosystems). The comparative CT method was used to determine fold differences between 
samples and the calibrator gene, ~-actin. 
Statistical analyses 
Results are reported as means ± SEM (n = 4-7). ANOVA with Bonferroni's post-hoc test 
(for parametric data) or Mann-Whitney Rank Sum test (for non parametric data) was used for the 
determination of statistical significance among treatment grou ps, as appropriate. A p value less 
than 0.05 was selected before the study as the level of significance. 
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RESULTS 
SFN treatment protected mice from necrosis caused by APAP 
Elevated plasma levels of transaminases (e.g., ALT and AST) indicate damage to cell 
membranes and may be evidence of widespread liver dysfunction.(31) As expected, APAP 
overdose caused an average elevation in circulating AL T of >200-fold, and an elevation in AST of 
-100-fold, compared with controls. However, pretreatment with sulforaphane attenuated the 
increase in transaminases. On average, sulforaphane-treated mice had roughly half the 
transaminase activity of mice that did not receive sulforaphane (Fig. 2). Transaminase data was 
paralleled by hepatic histology, as assessed by hematoxylin and eosin staining (Fig. 3A). APAP 
caused necroinflammatory liver damage at pericentral regions of the liver in all mice, but the size 
of the necrotic areas was visibly diminished by SFN. APAP overdose also caused an increase in 
hemorrhagic necrosis, which is seen after chloroacetate esterase staining as an infiltraticrh of red 
blood cells into necrotic areas (Fig. 38). SFN reduced the extravasation of red blood cells from 
pericentral foci, consistent with the observed changes in AL T, AST, and cellular morphology. 
SFN decreased indices of oxidative stress 
Glutathione is the first line of defense against APAP toxicity(32): APAP's toxic metabolite 
NAPQI is primarily removed by conjugation with GSH. In an experiment comparing the effects of 
SFN alone to control treatment, SFN was found to increase total hepatic glutathione (>1.2x on 
average; Fig. 4). A similar effect on glutathione was seen after APAP overdose. In control mice 
that were fasted overnight, glutathione content was measured at -3400 nmol/gram of tissue. 
After APAP injection, glutathione was reduced by half (-1500 nmol/g). With previous SFN 
administration, however, glutathione depletion was blunted (-2500 nmol/g) (Fig. 5, GSH+GSSG). 
7 
Glutathione reductase activity was also significantly reduced by APAP. Enzyme activity 
in control mice averaged 35 units/g protein, but APAP overdose reduced this activity to -27 U/g. 
SFN pretreatment maintained the catalytic activity of GR at 35 U/g even after APAP (Fig. 5, GR). 
Lipid peroxidation strongly correlates with the availability of glutathione.(33; 34) As expected, the 
lipid peroxidation product 4-hydroxynonenal was detected over a substantial area of liver tissue 
after APAP intoxication (Fig. 6). Though the characteristic brown stain indicating membrane lipid 
oxidation was present in all animals after APAP injection, this staining was more diffuse in mice 
that were pretreated with SFN. Lipid peroxidation, like necrosis, was largely confined to 
pericentral areas of the liver. 
SFN did not inhibit CYP2E1, but induced Nrf2 
The microsomal drug-metabolizing enzyme Cytochrome P450 2E1 (CYP2E1), found 
abundantly in the liver, is the primary P450 isozyme involved in NAPQI formation. 
Correspondingly, many of the substances that prevent APAP intoxication work by inhibiting 
CYP2E1 and therefore reducing the formation of NAPQI. At this dose of SFN, however, no 
inhibition of CYP2E-1 was observed (Fig. 7). The average activity of CYP2E1 protein in water-
treated mice was 0.57 nmol/mg/min. In comparison the average CYP2E1 activity of SFN-treated 
mice was 0.54 nmol/mg/min, which was not statistically different. 
Though SFN had no apparent effect on CYP2E1, it caused a robust increase in Nrf2 
protein (Fig. 8). Six hours after SFN treatment, Nrf2 was present in both nuclear and cytosolic 
cell fractions at levels roughly 2x greater than control. The ratio of nuclear Nrf2 to cytosolic Nrf2 
was unaffected by treatment. 
SFN did not significantly increase the mRNA levels of antioxidant genes 
Because Nrf2 is a transcription factor for antioxidant-related genes, the mRNA levels of 
such genes should indirectly indicate the presence of Nrf2 in the nucleus. Two well-studied 
antioxidant genes were chosen as potential representatives of increased nuclear localization: 
heme oxygenase 1 (HO-1) and NAD(P)H:quinone oxidoreductase 1 (Nq01). 
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Six hours after SFN there is an apparent trend toward increased transcription of Nqo1 
and HO-1. This trend is not observed at 24 hours after SFN. At neither time was there a 
significant difference in transcription between treated subjects and controls. 
9 
DISCUSSION 
Oxidative stress is a known mediator of several pathologies, such as drug-induced liver 
failure. In spite of this, it has been shown that compounds that directly interact with oxidant 
species are often ineffective, and at times may worsen clinical outcomes. Sulforaphane was 
used here to investigate the ability of indirect antioxidants to prevent liver injury due to 
acetaminophen overdose. In contrast to direct antioxidants, SFN prevented liver damage and 
decreased the levels of several biomarkers for oxidative stress. 
As explained in the Introduction, SFN is hypothesized to act through Nrf2, a transcription 
factor for antioxidant genes. The immunoblot data presented here support this hypothesis. After 
SFN administration, Nrf2 levels increased in both the nucleus and the cytoplasm. The increase in 
nuclear Nrf2 may be due to SFN's purported ability to induce conformational change in Keap1, 
which would allow Nrf2 to move into the nucleus for the purposes of DNA binding. Additionally, 
the increase in cytosolic Nrf2 supports the finding of Purdom-Dickinson et al. that enhanced 
translation of Nrf2 is a central feature of the antioxidant response.(35) 
In parallel to its direct effect on Nrf2, SFN acted on some of the downstream targets of 
the transcriptional pathway. Mice treated with SFN had substantial augmentation of total cellular 
glutathione and glutathione reductase activity. These same mice were also protected from liver 
injury. Implied here is a specific, Nrf2-mediated mechanism by which SFN was protective. 
Maintenance of cellular thiols is especially important after acetaminophen overdose. SFN-treated 
animals maintained total cellular glutathione better than untreated animals; therefore, they were 
better able to remove the toxic APAP metabolite NAPQI before it could cause more extensive 
hepatic damage. 
It must be noted that SFN, for all of its effects on Nrf2 and Nrf2's downstream targets, did 
not appear to influence mRNA levels of the antioxidant genes Nqo 1 and HO-1. The reason for 
this is not immediately clear and might be attributed to several variables. Response to SFN has 
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been shown to differ according to species, target tissue, dose, and method of administration. 
Thimmulappa et al. reported an increase in hepatic Nq01 mRNA after giving SFN i.g. at a dose of 
9 ~mol/mouse/day x 7 days. (36) Robbins et al. reported no such increase in mRNA after 2 weeks 
of feeding a standardized diet which provided a dose of 18.96 ~mol total glucosinolates/day.(37) 
The dose chosen for this experiment - 10 mg/kg/day - is in between those chosen by 
Thimmulappa and Robbins, being equivalent to 56.4 ~mol/kg/day. Due to the different times and 
routes of administration used in each study, however, it is difficult to extrapolate a cause for the 
variation in Nq01 mRNA levels. Furthermore, at this time there are no published studies of 
hepatic mRNA expression using SFN at or near 10 mg/kg. In the future it will be necessary to test 
a wider assortment of genes over a range of doses so that SFN's effects on gene expression may 
be better characterized. 
Taken together, the results of this study indicate that SFN prevents acute liver injury after 
acetaminophen overdose. Specifically, SFN protected the liver by preventing the oxidative stress 
that invariably precedes APAP-induced hepatic failure. The data presented here support the role 
of alleviation of oxidative stress in APAP overdose and suggest a potential role for indirect 
antioxidants in clinical practice. 
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SUMMARY AND CONCLUSIONS 
APAP overdose is the leading cause of fulminant hepatic failure,(38) yet there are few 
viable approaches to treating or preventing APAP-related liver injury. The FDA's approval in 1985 
of oral n-acetylcysteine (NAC) remains an important medical breakthrough, but aside from the 
introduction of an injectable form of NAC in 2004, there have been no new drugs specifically 
indicated for APAP overdose in over 20 years. Meanwhile, the incidence of APAP-related toxicity 
shows no signs of decline,(39; 40) so there is still a need for new and innovative therapies. 
One potential new therapy for APAP toxicity is the use of Nrf2 inducers. Numerous 
studies, several of which are referenced in this text, identify Nrf2 induction as a critical mediator of 
drug and xenobiotic metabolism. The experiments described here build on those earlier studies 
by demonstrating the application of the Nrf2 inducer SFN in a model of APAP overdose. The 
fundamental goal of this work was to determine the potential toxicologic utility ofNrf2 inducers 
such as SFN. 
At this time there is no established protocol for administration of Nrf2 inducers in cases of 
liver injury. The ultimate development of new therapies for APAP-induced hepatic failure will 
require extensive additional research. These data, however, represent a small step toward the 
realization of a new approach to a widespread and costly public health problem. By 
demonstrating the efficacy of sulforaphane in vivo, this work provides further proof of concept for 







Fig. 1: Simplified model of Nrf2 induction by sulforaphane 
Sulforaphane's (SFN) electrophilic side chain alkylates cysteine residues on 
Keap1. The conformational change induced in Keap1 allows the release of its 
binding partner, Nrf2. Unbound Nrf2 translocates to the nucleus and binds to 




























APAP + + 
SFN + + 
Fig. 2: Effect of acetaminophen and sulforaphane on plasma parameters 
Male C57BU6J mice were pretreated with water or sulforaphane for 4 days and 
injected with APAP or saline vehicle on day 5 as described in Methods. The 
plasma AL T and AST levels were analyzed. Data are means ± SEM (n = 4-6). 
ap<O.05 compared to saline injection; bp<O.05 compared to APAP alone. 
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A Water SFN 
B Water SFN 
Fig. 3: Effect of acetaminophen and sulforaphane on hepatic ultrastructure 
Representative photomicrographs (200x) of hematoxylin and eosin (panel A) and 
chloroacetate esterase (panel 8) are shown. Inflammation and coagulative 












Fig. 4: Effect of SFN on total hepatic glutathione 
Male C57BU6J mice were pretreated with water or SFN for 4 days and sacrificed 
6h after last treatment, as described in Methods. Total glutathione was 
determined by spectrophotometry. Data are means ± SEM (n = 4). ap<O.05 
compared to water alone 
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Fig. 5: Effect of APAP and SFN on glutathione content and synthesis 
Hepatic levels of total glutathione and glutathione reductase activity were 
determined by spectrophotometry. Data are means ± SEM (n = 4). ap<O.05 
compared to saline injection; bp<O.05 compared to APAP alone 
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Water SFN 
Fig. 6: Effect of APAP and SFN on membrane lipid peroxidation 
Adducts of 4-hydrox¥nonenal were detected by immunohistochemistry as 











Fig. 7: CYP2E1 activity 
Activity of the microsomal enzyme CYP2E 1 was determined by observing the 
conversion of p-nitrophenol to 4-nitocatechol. Data are reported as means ± SEM 
(n = 4). 
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Fig. 8: Nuclear accumulation of Nrf2 
Male C57BLl6J mice were treated with water or SFN alone and immunoblots 
were performed as described in Methods. Representative immunoblots for Nrf2 
at the 6 h time point are shown (top panel). Nrf2 protein levels were normalized 
to loading controls and quantified by densitometry (bottom panels). 
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